Clinical Trial Update: Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms [NA]

View source ↗

Summary

A completed clinical trial evaluating the impact of Soloways omega-3 fatty acid supplementation on lipid parameters in adults with PPARG polymorphisms and LDL-t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperlipoproteinemia Ldl Type
• Triglyceride Storage Disease Type
• Triglyceride Storage Disease Type Ii

Drugs mentioned

• Soloways Omega-3 Fatty Acid Supplement (Omega-3 fatty acids)

Snippet

Sponsor: S.LAB (SOLOWAYS) | Conditions: LDL Hyperlipoproteinemia, Low-Density-Lipoprotein-Type [LDL] Hyperlipoproteinemia | NA | Status: COMPLETED